Beverly Teicher

23PUBLICATIONS
102CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)English languagePredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (23)

|Nov 05, 2026
Variant-Selective and Pan-RAS Inhibitors Enhance Targeted Agent Activity in Patient-Derived Multi-cell-type Tumor Spheroids.

|Oct 07, 2026
Variant-selective and pan-RAS inhibitors enhance targeted agent activity in patient-derived multi-cell type tumor spheroids.

|Apr 06, 2026
Preclinical Activity of the B7-H3-Targeting Antibody-Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors.

Edward Favours, Haiying Tang, Peyton Wong

|Mar 04, 2026
Improving Preclinical Cancer Drug Development Models to Avoid Clinical Failure.

David A Gewirtz, Beverly Teicher, Edward Greenberg

|Feb 19, 2026
Endosialin (CD248) Cancer Role and Therapeutics: 33 Years on.

Beverly A Teicher, Li Chen, Dianne L Newton

|Feb 13, 2026
Targeting Pediatric Glioblastomas by Combining OLIG2 Inhibitor CT-179 with Fractionated Radiation in a Panel of Patient-Derived Orthotopic Xenograft Mouse Models.

Holly Lindsay, Yuchen Du, Lin Qi

Pageof 4

Frequent Collaborators

9 joint publications

Kenneth C Anderson

9 joint publications

Lewis C Cantley

9 joint publications

Riccardo Dalla-Favera

9 joint publications

Chi Van Dang